| Literature DB >> 27931192 |
Y Hazlina1, M A Marlindawati2, K Shamsuddin3.
Abstract
BACKGROUND: Malaysia still faces challenges optimizing resources to effectively eliminate measles through high immunization and herd immunity, with sporadic outbreaks of measles as evidence. The objective of this study is to determine the age-specific positive measles antibodies seroprevalence used for assessing the establishment of herd immunity against measles in different age groups. This is useful for identifying vulnerable age groups requiring supplementary immunization.Entities:
Keywords: Herd immunity; Measles; Measles IgG antibody; Seroprevalence
Mesh:
Substances:
Year: 2016 PMID: 27931192 PMCID: PMC5144497 DOI: 10.1186/s12879-016-2069-y
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Association between socio-demographic characteristics and medical/ medication history and seroprevalence of measles antibodies (measles IgG titre), (n = 1541)
| Characteristics | Seroprevalence of measles IgG titre | |||||||
|---|---|---|---|---|---|---|---|---|
| N(%) | Positive titrea (95% CI) | Indeterminate and negative titresb (95% CI) | Crude odds ratio (95% CI) |
| ||||
| Total | 1541(100) | 87% | (85–89) | 13% | (11–15) | |||
| Age (year) | ||||||||
| [6–9] | 298 (19.3) | 90% | (87–94) | 10% | (6–13) | 1.00 | ||
| 15–24 | 489 (31.7) | 74% | (70–78) | 26% | (22–30) | 0.31 | (0.20 – 0.47) | 0.0001 |
| 45–54 | 754 (48.9) | 94% | (92–96) | 6% | (4–8) | 1.74 | (1.07 – 2.84) | 0.027 |
| Gender | ||||||||
| [Male] | 721 (46.8) | 85% | (83–88) | 15% | (12–17) | 1.00 | ||
| Female | 820 (53.2) | 88% | (86–91) | 12% | (9–14) | 1.30 | (0.97 – 1.75) | 0.083 |
| Ethnicity | ||||||||
| [Non-Malay] | 614 (39.8) | 89% | (87–92) | 11% | (8–13) | 1.00 | ||
| Malay | 927 (60.2) | 86% | (83–88) | 14% | (12–17) | 0.73 | (0.54–1.00) | 0.050 |
| Education Level | ||||||||
| [Lower] | 1144 (74.2) | 88% | (87–90) | 12% | (10–13) | 1.00 | ||
| Higher | 397 (25.8) | 83% | (79–87) | 17% | (13–21) | 0.65 | (0.47–0.89) | 0.008 |
| Household income | ||||||||
| [Lower] | 1157 (75.1) | 86% | (84–88) | 14% | (12–16) | 1.00 | ||
| Higher | 384 (24.9) | 89% | (86–92) | 11% | (8–14) | 1.29 | (0.90–1.85) | 0.170 |
| Place of birth | ||||||||
| [Others] | 839 (54.4) | 89% | (87–91) | 11% | (9–13) | 1.00 | ||
| Seremban | 702 (45.6) | 85% | (82–88) | 15% | (12–18) | 0.71 | (0.53–0.96) | 0.024 |
| Locality of place of birth | ||||||||
| [Urban] | 1017 (66.0) | 86% | (84–88) | 14% | (12–16) | 1.00 | ||
| Rural | 524 (34.0) | 89% | (86–92) | 11% | (8–14) | 1.30 | (0.94–1.81) | 0.110 |
| Locality of health clinics attended | ||||||||
| [Urban] | 1258 (81.6) | 87% | (86–89) | 13% | (11–14) | 1.00 | ||
| Rural | 283 (18.4) | 86% | (81–90) | 14% | (10–19) | 0.85 | (0.59–1.24) | 0.404 |
| Medical problems | ||||||||
| [No] | 941 (61.1) | 84% | (81–86) | 16% | (14–19) | 1.00 | ||
| Yes | 600 (38.9) | 92% | (90–94) | 8% | (6–10) | 2.22 | (1.57–3.12) | 0.0001 |
| Medication history | ||||||||
| [No] | 976 (63.3) | 84% | (81–86) | 16% | (14–19) | 1.00 | ||
| Yes | 565 (36.7) | 93% | (90–95) | 7% | (5–10) | 2.41 | (1.68–3.43) | 0.0001 |
[] Reference group
aPositive titre: > 220 IU/ml
bIndeterminate titre 120–220 IU/ml and negative titre < 120 IU/ml
Seroprevalence of positive measles antibodies (p), critical prevalence of antibodies associated with herd immunity (pc) and establishment of herd immunity (HI) - comparing worst, best and absolute case scenario
| Characteristics | Establishment of herd immunity (HI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Worst Casea ( | Best Caseb ( | Absolute Casec ( | |||||||
|
| pc (%) (range) | HI |
| pc (%) (range) | HI |
| pc (%) (range) | HI | |
| Total | 87.0 (85.0–89.0) | 89.4 (87.9–90.8) | - | 93.0 (92.0–94.0) | 89.1 (87.6–0.5) | + | 93.0 (91.0–94.0) | 89.1 (87.6–90.5) | + |
| Age (year) | |||||||||
| 6–9 | 90.0 (87.0–94.0) | 89.2 (87.4–90.7) | + | 95.0 (92.0–97.0) | 89.0 (87.6–90.5) | + | 95.0 (92.0–97.0) | 89.0 (87.6–90.5) | + |
| 15 – 24 | 74.0 (70–78) | 90.4 (88.9–91.8) | - | 85.0 (82.0–89.0) | 89.5 (88.0–90.9) | - | 84.0 (80.0–87.0) | 89.5 (87.6–90.5) | - |
| 45–54 | 94.0 (92.0–96.0) | 89.0 (87.6–90.5) | + | 97.0 (96.0 – 98.0) | 88.9 (87.5–90.4) | + | 97.0 (96.0–98.0) | 88.9 (87.5–90.4) | + |
| Gender | |||||||||
| Male | 85.0 (83.0–88.0) | 89.5 (88.0–90.9) | - | 92.0 (90.0–94.0) | 89.1 (87.7–90.6) | + | 92.0 (89.0–94.0) | 89.1 (87.7–90.6) | + |
| Female | 88.0 (86.0–91.0) | 89.3 (87.9–90.7) | - | 94.0 (92.0–96.0) | 89.0 (87.6–90.5) | + | 94.0 (92.0–95.0) | 89.0 (87.6–90.5) | + |
| Ethnicity | |||||||||
| Malay | 86.0 (83.0–88.0) | 89.4 (87.9–90.8) | - | 92.0 (91.0–94.0) | 89.1 (87.7–90.6) | + | 92.0 (90.0–94.0) | 89.1 (87.7–90.6) | + |
| Chinese | 90.0 (85.0–94.0) | 89.2 (87.8–90.7) | + | 93.0 (90.0–97.0) | 89.1 (87.6–90.5) | + | 93.0 (90.0–97.0) | 89.1 (87.6–90.5) | + |
| Indian | 89.0 (85.0–92.0) | 89.3 (87.8–90.7) | - | 94.0 (92.0–97.0) | 89.0 (87.6–90.5) | + | 94.0 (92.0–97.0) | 89.0 (87.6–90.5) | + |
| Others | 93.0 (83.0–103.0) | 89.1 (87.6–90.5) | + | 96.0 (89.0–104.0) | 88.8 (87.4–90.4) | + | 96.0 (89.0–104.0) | 88.8 (87.4–90.4) | + |
aAssuming all indeterminate results are negative,b Assuming all indeterminate results are positive, cIneterminate result are not presented
(p) Seroprevalence of positive measles antibodies; (pc) Critical prevalence of antibodies associated with herd immunity
(HI) Herd Immunity; + Herd Immunity Established (p > mean pc); - Herd Immunity Not Established (p < mean pc)
Calcualted using Critical Prevalence of Protected Individuals, Ic (%) = 92.5 (91–94)
Malaysian immunization program by birth cohort
| Age group (years) | Birth cohort | Immunization program in Malaysia |
|---|---|---|
| 45–54 | Born in 1960–1969 | • No measles vaccination program in Malaysia |
| 15–24 | Born in 1990–1999 | • Single dose measles vaccination was given to children at 9 months old |
| 6–9 | Born in 2006–2009 | • Received two doses MMR vaccine; once at 12 months and the second at 7 years of age |